MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type
Jiayu Li(Zhejiang Chinese Medical University), Fred R. Hirsch(Tisch Hospital), Shengxiang Ren(Tongji University), Xiu Chen(Guangxi Medical University), Yishi Zhang(Children's Hospital of Chongqing Medical University), Ningning Cheng(Tongji University), Xuefei Li(Harbin Medical University), Chao Zhao(Tongji University), Xiaoxia Chen(Guangdong Academy of Medical Sciences), Yinmin Zhao(Tongji University), Caicun Zhou(Tongji University), Mingchuan Zhao(Tongji University), Fei Zhou(Shanghai University)
Cited by 57
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2006|705